To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.
Status:
Recruiting
Trial end date:
2023-12-22
Target enrollment:
Participant gender:
Summary
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and
tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants
with MDS or MM who are transfusion-dependent or present with symptomatic anemia.